Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CO-ANNEXIN study of intravenous ANXV in hospitalized adults with moderate to severe COVID-19
NL-OMON51226Phase 2Not yet recruiting
- Sponsor
- Maastricht University Medical Center+
- Start
- Nov 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of annexin a5 in coronavirus disease 2019 (COVID-19) and coronavirus pneumonia, sponsored by Maastricht University Medical Center+. Primary endpoints: Activated coagulation factor-antithrombin complexes, Cytokine and inflammatory profile and 17 more. Planned start Nov 2021; status: not yet recruiting.
02
Drugs
annexin a5
03
Conditions
coronavirus disease 2019 (COVID-19)coronavirus pneumonia
Beyond the preview
Go deeper on NL-OMON51226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51226.